DOCSLIB.ORG

Clinical Immunity in Bone and Joints

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Immunity in Bone and Joints Journal of Bone and Mineral Metabolism (2019) 37:2–8 https://doi.org/10.1007/s00774-018-0965-5 INVITED REVIEW Clinical immunity in bone and joints Yoshiya Tanaka1 Received: 3 September 2018 / Accepted: 24 September 2018 / Published online: 15 October 2018 © The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018 Abstract The immune system and bone metabolism infuence each other. An imbalance in the immune system, resulting in infamma- tory stimuli may induce an imbalance in bone turnover via induction of osteoclast diferentiation and inhibition of osteoblast diferentiation, leading to various pathological conditions including osteoporosis. T-cell subsets, helper T (Th)1 and Th17, which activate the immune system, induce osteoclasts, whereas regulatory T (Treg) cells, responsible for immunosuppres- sion, inhibit osteoclastic diferentiation. In addition, infammatory cytokines, such as the tumor necrosis factor (TNF), also cause an imbalance in bone turnover, induction of osteoclasts and inhibition of osteoblasts. Treatments targeting the immune system may regulate abnormalities in bone metabolism, while also controlling immune abnormalities. In rheumatoid arthritis (RA), a representative autoimmune disease, immune abnormality and accompanying prolongation of synovial infammation cause bone and cartilage destruction, periarticular osteoporosis, and systemic osteoporosis. Joint damage and osteoporosis in RA occur through totally diferent mechanisms. Stimulation by infammatory cytokines induces the expression of the receptor activator for nuclear factor-κB ligand (RANKL) in T cells and synovial cells, thereby inducing bone destruction due to osteoblast-independent osteoclast maturation. However, biological products targeting TNF or interleukin-6 not only control disease activity, but also inhibit joint destruction. However, these biological products are not efective for osteopo- rosis. Conversely, anti-RANKL antibody inhibits osteoporosis and bone destruction, but exerts no infuence on RA disease activity. Such diferences in therapeutic efcacy may indicate the necessity for rethinking current theories on the mechanism of bone metabolism abnormality and joint destruction. Understanding the mechanisms underlying these pathologies via com- monalities existing between the immune system and the metabolic system may lead to the development of new treatments. Keywords Bone · Joint · Immunity · Rheumatoid arthritis · Osteoporosis Introduction immunity mechanisms which can process a variety of anti- gen information and memorize such information in prepa- The immune system is a biological defense mechanism ration for a second invasion in addition to self-tolerance. against foreign antigens established during several million Thymus-derived naive T cells diferentiate into memory years of evolution, starting from microorganisms. Natural T-cells that retain the memory of antigen information and immunity is a primitive mechanism originating in micro- homing information from dendritic cells in regional lymph organisms. This mechanism allows the macrophages, neu- nodes. Memory T-cells circulate into peripheral tissues, and trophils, and NK cells, among others, to recognize bacteria quickly take charge of the immune response, using memo- and viruses that invade the host, and eliminate them via rized antigen information. In contrast, T cells show immune processes such as phagocytosis, enzymatic treatment, and tolerance to autoantigens. However, if such self-tolerance is production of active oxygen among others. On the other broken by some factor, autologous reactive T cells will be hand, vertebrates evolved the immune system, and acquired activated to stimulate B cells to induce the production of autoantigens, causing autoimmunity. The immune system is involved in the maintenance of * Yoshiya Tanaka normality, prevention of various pathological conditions via [email protected]‑u.ac.jp initiation of biological defense and formation and resolution 1 The First Department of Internal Medicine, School of infammation. The immune system and the metabolic sys- of Medicine, University of Occupational and Environmental tem are both important biological regulatory mechanisms, Health, Japan, 1‑1 Iseigaoka, Kitakyushu 807‑8555, Japan Vol:.(1234567890)1 3 Journal of Bone and Mineral Metabolism (2019) 37:2–8 3 and an abnormality in the immune system may infuence through blood fow, mature to become polynuclear osteo- the metabolic system. In autoimmune infammatory con- clasts, in response to stimulation by the receptor activator for ditions, caused by immune abnormalities such as rheuma- nuclear factor-κB ligand (RANKL) expressed in osteoblasts toid arthritis (RA), bone metabolism abnormalities may be and osteocytes, and when activated, induce bone resorption induced via immunocompetent cells and cytokines, resulting (Fig. 1). in consequent bone and joint destruction [1–5]. However, Homeostasis of bone tissue is maintained bone remod- current understanding of the pathology of RA and advances eling cycle (bone turnover) of bone resorption by osteoclasts in treatment indicate that bone and cartilage destruction and and bone formation by osteoblasts, via regulatory mecha- osteoporosis are caused by totally diferent mechanisms, nisms that include the endocrine system [6–12] (Fig. 2). requiring diferent therapeutic strategies. This paper presents Various factors produced by osteocytes such as TGF-β an outline of the infuence of the immune system on bone and BMP also induce the diferentiation of mesenchymal metabolism as well as the related therapeutic processes, stem cells into osteoblasts and osteocytes, bone modeling. while focusing on the pathology of RA. In addition, sclerostin and Dickkopf (DKK)-1 produced by osteocytes inhibit Wnt-mediated signals expressed in osteo- Mechanism of bone metabolism blast precursors to control the diferentiation and activation of osteoblasts. Osteocytes, which account for about 95% of The skeleton is the structure that supports the body. It is all cell components in bone, possess many dendrites which also the organ in which bone and mineral metabolism take support the three-dimensional structure of bone, thus play- place. Bone and hard tissues impart structural rigidity and ing a central role in both modeling and remodeling of bone. form to vertebrates, and enable bone and mineral metabo- Abnormalities in modeling and remodeling may lead to lism which is vital for life. Bone tissue is composed of the abnormal bone metabolism, resulting in conditions such as bone matrix consisting of type I collagen with hydroxyapa- osteoporosis. tite crystal deposits and cell groups such as osteoblasts and osteocytes. Osteoblasts, which diferentiate from mesen- Infuence of rheumatoid arthritis on bone chymal stem cells to produce the bone matrix, diferentiate metabolism further into osteocytes which play a key role in maintaining bone structure. Osteoclasts are derived from hematopoietic Rheumatoid arthritis is a systemic autoimmune disease stem cells. Precursor monocytes, which migrate into bone with synovitis in multiple joints as its principal pathological M-CSF, IL-6, IL-17, TNF, Activated PGE2 Hematopoietic Osteoclast precursor osteoclast stem cell (monocyte) RANK RANKL TGF, BMP Anti-RANKL Wnt Mesenchymal osteoblast osteocyte Stem cell Bone matrix Bone matrix TNF, DKK-1, sclerostin IL-1, IL-6, IL-7, IL-17, TNF, PGE2 Anti-TNF Anti-TNF, anti-IL-6R Fig. 1 Diferentiation of osteocyte and osteoclast and its regulation. targeting TNF and IL-6 inhibit bone destruction, but they do not exert Osteoblasts and osteocytes diferentiate from mesenchymal stem cells any infuence on systemic osteoporosis. The anti-RANKL antibody, to produce the bone matrix and osteoclasts derived from hematopoi- denosumab, also inhibits the process of osteoclast maturation by etic stem cells are involved in bone resorption. Biological DMARDs RANKL expressed in synovial cells and T cells 1 3 4 Journal of Bone and Mineral Metabolism (2019) 37:2–8 PTH Anti-SOST resting osteoblast TNFα, IL-6 Anti-TNF Anti-IL-6(R) Bone formation Activation of osteoclast Activated osteoclast Activated osteoclast bisphosphonate Anti-RANKL osteoporosis (osteoblast-dependent, TNF-independent) Anti-RANKL Bone damage in RA (osteoblast-independent, TNF-dependent) Fig. 2 Mechanisms and treatment strategies of osteoporosis and joint ated with RA represents the maturation of osteoclasts enhanced in an damage in RA. Homeostasis of bone is maintained bone remodeling osteoblast-independent manner, demonstrating deviation from bone cycle of bone resorption by osteoclasts and bone formation by osteo- turnover due to stimulation by TNF and IL-6 blasts via regulatory mechanisms. However, bone destruction associ- feature. This disease occurs frequently in women in their Helper T (Th)1 and Th17 cells induce osteoclasts via the 30s and 50s, where the total number of patients is estimated production of TNF and IL-17, and Th1 cells inhibit the to be about 7–800,000 in Japan. Clinical symptoms of RA expression of osteoprotegerin (OPG) via the production of such as pain, swelling, and stifness of multiple joints and interferon (IFN)-γ (Fig. 3). In contrast, regulatory T (Treg) joint deformity markedly impair the daily-life activities of cells inhibit the diferentiation of osteoclasts by express- patients. Joint destruction begins to progress from early ing cytotoxic T-lymphocyte antigen-4. In addition, trans- stages of RA-onset, and resulting joint deformities may forming
Load more

Recommended publications
  • Ncf1 Affects Osteoclast Formation but Is Not Critical for Postmenopausal
    Stubelius et al. BMC Musculoskeletal Disorders (2016) 17:464 DOI 10.1186/s12891-016-1315-1 RESEARCH ARTICLE Open Access Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss Alexandra Stubelius1*, Annica Andersson1, Rikard Holmdahl3, Claes Ohlsson2, Ulrika Islander1 and Hans Carlsten1 Abstract Background: Increased reactive oxygen species and estrogen deficiency contribute to the pathophysiology of postmenopausal osteoporosis. Reactive oxygen species contribute to bone degradation and is necessary for RANKL- induced osteoclast differentiation. In postmenopausal bone loss, reactive oxygen species can also activate immune cells to further enhance bone resorption. Here, we investigated the role of reactive oxygen species in ovariectomy- induced osteoporosis in mice deficient in Ncf1, a subunit for the NADPH oxidase 2 and a well-known regulator of the immune system. Methods: B10.Q wild-type (WT) mice and mice with a spontaneous point mutation in the Ncf1-gene (Ncf1*/*) were ovariectomized (ovx) or sham-operated. After 4 weeks, osteoclasts were generated ex vivo, and bone mineral density was measured using peripheral quantitative computed tomography. Lymphocyte populations, macrophages, pre-osteoclasts and intracellular reactive oxygen species were analyzed by flow cytometry. Results: After ovx, Ncf1*/*-mice formed fewer osteoclasts ex vivo compared to WT mice. However, trabecular bone mineral density decreased similarly in both genotypes after ovx. Ncf1*/*-mice had a larger population of pre- osteoclasts, whereas lymphocytes were activated to the same extent in both genotypes. Conclusion: Ncf1*/*-mice develop fewer osteoclasts after ovx than WT mice. However, irrespective of genotype, bone mineral density decreases after ovx, indicating that a compensatory mechanism retains bone degradation after ovx.
    [Show full text]
  • Heart Failure and Drug-Induced Lupus
    Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush John J. Cush, MD, Chief, Rheumatology ABSTRACT demyelinating disease, cytopenias, auto- and Clinical Immunology, Presbyterian Serious and unexpected adverse events, immune disorders, and heart failure. Hospital of Dallas, Clinical Professor of such as heart failure and drug-induced Other essays in this volume address the Internal Medicine, The University of Texas lupus, have been reported in patients subject of infection (10), demyelination Southwestern Medical School, Dallas, Texas, USA. receiving TNF inhibitor therapy. These (11), and lymphoma (12). This review events generally are easily recogniz- will focus on heart failure and lupus- Please address correspondence to: John J. Cush, MD, Presbyterian Hospital able, although they cannot be predicted like disease, which are rarely seen in of Dallas, 8200 Walnut Hill Lane, Dallas, nor avoided, other than by drug avoid- association with TNF inhibitor therapy Texax 75231-4496, USA. ance altogether. Many patients have and are currently without explanation. Clin Exp Rheumatol 2004; 22 (Suppl. 35): great benefit from anti-TNF therapies. S141-S147. Their intelligent use requires a firm Sources of data © Copyright CLINICAL AND EXPERIMENTAL understanding of these rare toxicities, As a consequence of drug approval, RHEUMATOLOGY 2004. so as to minimize the morbidity associ- manufacturers have a responsibility to ated with their uncommon occurrence. collect safety data actively and report Key words: TNF inhibitors, conges- these data to the appropriate agencies. tive heart failure, drug-induced lupus, Introduction For example, in the USA a manufactur- rheumatoid arthritis. The introduction of biologic agents to er must submit periodic safety reports specifically inhibit the pro-inflammato- to the FDA twice yearly (March and ry cytokine, tumor necrosis factor (TNF), September).
    [Show full text]
  • Formation of Osteoclast-Like Cells from Peripheral Blood of Periodontitis Patients Occurs Without Supplementation of Macrophage Colony-Stimulating Factor
    J Clin Periodontol 2008; 35: 568–575 doi: 10.1111/j.1600-051X.2008.01241.x Stanley T. S. Tjoa1, Teun J. de Formation of osteoclast-like cells Vries1,2, Ton Schoenmaker1,2, Angele Kelder3, Bruno G. Loos1 and Vincent Everts2 from peripheral blood of 1Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), Universiteit van Amsterdam and Vrije periodontitis patients occurs Universteit, Amsterdam, The Netherlands; 2Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), without supplementation of Universiteit van Amsterdam and Vrije Universteit, Amsterdam, Research Institute MOVE, The Netherlands; 3Department of Hematology, VUMC, Vrije Universiteit, macrophage colony-stimulating Amsterdam, The Netherlands factor Tjoa STS, de Vries TJ, Schoenmaker T, Kelder A, Loos BG, Everts V. Formation of osteoclast-like cells from peripheral blood of periodontitis patients occurs without supplementation of macrophage colony-stimulating factor. J Clin Periodontol 2008; 35: 568–575. doi: 10.1111/j.1600-051X.2008.01241.x. Abstract Aim: To determine whether peripheral blood mononuclear cells (PBMCs) from chronic periodontitis patients differ from PBMCs from matched control patients in their capacity to form osteoclast-like cells. Material and Methods: PBMCs from 10 subjects with severe chronic periodontitis and their matched controls were cultured on plastic or on bone slices without or with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kB ligand (RANKL). The number of tartrate-resistant acid phosphatase-positive (TRACP1) multinucleated cells (MNCs) and bone resorption were assessed. Results: TRACP1 MNCs were formed under all culture conditions, in patient and control cultures. In periodontitis patients, the formation of TRACP1 MNC was similar for all three culture conditions; thus supplementation of the cytokines was not needed to induce MNC formation.
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH PrXELJANZ® tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate) PrXELJANZ® XR tofacitinib extended-release, tablets, oral 11 mg tofacitinib (as tofacitinib citrate) ATC Code: L04AA29 Selective Immunosuppressant Pfizer Canada ULC Date of Preparation: 17,300 Trans-Canada Highway October 24, 2019 Kirkland, Quebec H9J 2M5 TMPF PRISM C.V. c/o Pfizer Manufacturing Holdings LLC Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2019 Submission Control No: 230976 XELJANZ/XELJANZ XR Page 1 of 80 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 ADVERSE REACTIONS..................................................................................................15 DRUG INTERACTIONS ..................................................................................................29 DOSAGE AND ADMINISTRATION..............................................................................34 OVERDOSAGE ................................................................................................................38 ACTION AND CLINICAL PHARMACOLOGY ............................................................38
    [Show full text]
  • Osteoimmunology in Rheumatoid and Psoriatic Arthritis: Potential Effects of Tofacitinib on Bone Involvement
    Clinical Rheumatology (2020) 39:727–736 https://doi.org/10.1007/s10067-020-04930-x REVIEW ARTICLE Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement Giovanni Orsolini1 & Ilaria Bertoldi2 & Maurizio Rossini1 Received: 14 October 2019 /Revised: 20 December 2019 /Accepted: 6 January 2020 /Published online: 22 January 2020 # The Author(s) 2020 Abstract Chronic inflammation, such as that present in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), leads to aberrations in bone remodeling, which is mediated by several signaling pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. In this light, pro-inflammatory cytokines are now clearly implicated in these processes as they can perturb normal bone remodeling through their action on osteoclasts and osteoblasts at both intra- and extra-articular skeletal sites. As a selective inhibitor of JAK1 and JAK3, tofacitinib has the potential to play a role in the management of rheumatic diseases such as RA and PsA. Preclinical studies have demonstrated that tofacitinib can inhibit disturbed osteoclas- togenesis in RA, which suggests that targeting the JAK-STAT pathway may help limit bone erosion. Evidence from clinical trials with tofacitinib in RA and PsA is encouraging, as tofacitinib treatment has been shown to decrease articular bone erosion. In this review, the authors summarize current knowledge on the relationship between the immune system and the skeleton before examining the involvement of JAK-STATsignaling in bone homeostasis as well as the available preclinical and clinical evidence on the benefits of tofacitinib on prevention of bone involvement in RA and PsA.
    [Show full text]
  • Arthritis and Coeliac Disease
    Ann Rheum Dis: first published as 10.1136/ard.44.9.592 on 1 September 1985. Downloaded from Annals of the Rheumatic Diseases 1985, 44, 592-598 Arthritis and coeliac disease J T BOURNE,' P KUMAR,2 E C HUSKISSON,' R MAGEED 3 D J UNSWORTH,3 AND J A WOJTULEWSKI4 From the Departments of 'Rheumatology and 2Gastroenterology, St Bartholomew's Hospital, West Smithfield, London ECIA 7BE; the 3Bone and Joint Research Unit, London Hospital Medical College, London El; and 4St Mary's Hospital, Eastbourne SUMMARY We report six patients with coeliac disease in whom arthritis was prominent at diagnosis and who improved with dietary therapy. Joint pain preceded diagnosis by up to three years in five patients and 15 years in one patient. Joints most commonly involved were lumbar spine, hips, and knees (four cases). In three cases there were no bowel symptoms. All were seronegative. X-rays were abnormal in two cases. HLA-type Al, B8, DR3 was present in five and B27 in two patients. Circulating immune complexes showed no consistent pattern before or after treatment. Coeliac disease was diagnosed in all patients by jejunal biopsy, and joint symptoms in all responded to a gluten-free diet. Gluten challenge (for up to three weeks) failed to provoke arthritis in three patients tested. In a separate study of 160 treated coeliac patients attending regular follow up no arthritis attributable to coeliac disease and no ankylosing was in a group spondylitis identified, though control of 100 patients with Crohn's disease thecopyright. expected incidence of seronegative polyarthritis (23%) and ankylosing spondylitis (5%) was found (p<0.01).
    [Show full text]
  • Conditions Related to Inflammatory Arthritis
    Conditions Related to Inflammatory Arthritis There are many conditions related to inflammatory arthritis. Some exhibit symptoms similar to those of inflammatory arthritis, some are autoimmune disorders that result from inflammatory arthritis, and some occur in conjunction with inflammatory arthritis. Related conditions are listed for information purposes only. • Adhesive capsulitis – also known as “frozen shoulder,” the connective tissue surrounding the joint becomes stiff and inflamed causing extreme pain and greatly restricting movement. • Adult onset Still’s disease – a form of arthritis characterized by high spiking fevers and a salmon- colored rash. Still’s disease is more common in children. • Caplan’s syndrome – an inflammation and scarring of the lungs in people with rheumatoid arthritis who have exposure to coal dust, as in a mine. • Celiac disease – an autoimmune disorder of the small intestine that causes malabsorption of nutrients and can eventually cause osteopenia or osteoporosis. • Dermatomyositis – a connective tissue disease characterized by inflammation of the muscles and the skin. The condition is believed to be caused either by viral infection or an autoimmune reaction. • Diabetic finger sclerosis – a complication of diabetes, causing a hardening of the skin and connective tissue in the fingers, thus causing stiffness. • Duchenne muscular dystrophy – one of the most prevalent types of muscular dystrophy, characterized by rapid muscle degeneration. • Dupuytren’s contracture – an abnormal thickening of tissues in the palm and fingers that can cause the fingers to curl. • Eosinophilic fasciitis (Shulman’s syndrome) – a condition in which the muscle tissue underneath the skin becomes swollen and thick. People with eosinophilic fasciitis have a buildup of eosinophils—a type of white blood cell—in the affected tissue.
    [Show full text]
  • Osteoimmunology: Interactions of the Bone and Immune System
    Osteoimmunology: Interactions of the Bone and Immune System Joseph Lorenzo, Mark Horowitz and Yongwon Choi Endocr. Rev. 2008 29:403-440 originally published online May 1, 2008; , doi: 10.1210/er.2007-0038 To subscribe to Endocrine Reviews or any of the other journals published by The Endocrine Society please go to: http://edrv.endojournals.org//subscriptions/ Copyright © The Endocrine Society. All rights reserved. Print ISSN: 0021-972X. Online 0163-769X/08/$20.00/0 Endocrine Reviews 29(4):403–440 Printed in U.S.A. Copyright © 2008 by The Endocrine Society doi: 10.1210/er.2007-0038 Osteoimmunology: Interactions of the Bone and Immune System Joseph Lorenzo, Mark Horowitz, and Yongwon Choi Department of Medicine and the Musculoskeletal Institute (J.L.), The University of Connecticut Health Center, Farmington, Connecticut 06030; Department of Orthopaedics (M.H.), Yale University School of Medicine, New Haven, Connecticut 06510; and Department of Pathology and Laboratory Medicine (Y.C.), The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 Bone and the immune system are both complex tissues that that the other system has on the function of the tissue they are respectively regulate the skeleton and the body’s response to studying. This review is meant to provide a broad overview of invading pathogens. It has now become clear that these organ the many ways that bone and immune cells interact so that a systems often interact in their function. This is particularly better understanding of the role that each plays in the devel- true for the development of immune cells in the bone marrow opment and function of the other can develop.
    [Show full text]
  • Modeling Osteoclast Defect and Altered Hematopoietic Stem Cell Niche in Osteopetrosis with Patient-Derived Ipscs
    Modeling Osteoclast Defect and Altered Hematopoietic Stem Cell Niche in Osteopetrosis with Patient-Derived iPSCs Inci Cevher Zeytin Hacettepe University Berna Alkan Hacettepe University: Hacettepe Universitesi Cansu Ozdemir Hacettepe University: Hacettepe Universitesi Duygu Cetinkaya Hacettepe University: Hacettepe Universitesi FATMA VISAL OKUR ( [email protected] ) Hacettepe University, Faculty of Medicine https://orcid.org/0000-0002-1679-6205 Research Keywords: Osteopetrosis, TCIRG1, iPSC, disease modeling, osteoclast, niche modeling, HSC Posted Date: March 9th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-258821/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/22 Abstract Background Patients with osteopetrosis present with defective bone resorption caused by the lack of osteoclast activity and hematopoietic alterations, but their bone marrow hematopoietic stem/progenitor cell and osteoclast contents might be different. Osteoclasts recently have been described as the main regulators of HSCs niche, however, their exact role remains controversial due to the use of different models and conditions. Investigation of their role in hematopoietic stem cell niche formation and maintenance in osteopetrosis patients would provide critical information about the mechanisms of altered hematopoiesis. We used patient-derived induced pluripotent stem cells (iPSCs) to model osteoclast defect and hematopoietic niche compartments in vitro. Methods iPSCs were generated from peripheral blood mononuclear cells of patients carrying TCIRG1 mutation. iPSC lines were differentiated rst into hematopoietic stem cells-(HSCs), and then into myeloid progenitors and osteoclasts using a step-wise protocol. Then, we established different co-culture conditions with bone marrow-derived hMSCs and iHSCs of osteopetrosis patients as an in vitro hematopoietic niche model to evaluate the interactions between osteopetrotic-HSCs and bone marrow- derived MSCs as osteogenic progenitor cells.
    [Show full text]
  • Β Homeostatic Function of IL-1 Osteoclast Precursors Identifies a +
    Direct Inhibition of Human RANK+ Osteoclast Precursors Identifies a Homeostatic Function of IL-1β This information is current as Bitnara Lee, Tae-Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo, of October 2, 2021. Jin-Hyun Woo, Sung Jae Choi, Young Ho Lee, Gwan Gyu Song, Jeongwon Sohn, Kyung-Hyun Park-Min, Lionel B. Ivashkiv and Jong Dae Ji J Immunol 2010; 185:5926-5934; Prepublished online 8 October 2010; doi: 10.4049/jimmunol.1001591 Downloaded from http://www.jimmunol.org/content/185/10/5926 Supplementary http://www.jimmunol.org/content/suppl/2010/10/08/jimmunol.100159 http://www.jimmunol.org/ Material 1.DC1 References This article cites 47 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/185/10/5926.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • PATIENT FACT SHEET TNF Inhibitors
    PATIENT FACT SHEET TNF Inhibitors TNF inhibitors are used worldwide to treat symptoms. TNF inhibitors can control inflammation in inflammatory conditions such as rheumatoid arthritis the joints, gastrointestinal tract and skin. There are six (RA), psoriatic arthritis, juvenile arthritis, inflammatory different TNF inhibitors that have been approved by bowel disease (Crohn’s and ulcerative colitis), ankylosing the FDA for the treatment of rheumatic diseases. To spondylitis and psoriasis. They reduce inflammation decrease side effects and costs, most patients with and can stop disease progression by targeting an mild or moderate disease are treated with methotrexate inflammation causing substance called Tumor Necrosis before adding or switching to a TNF inhibitor. These WHAT IS IT? Factor (TNF). In healthy individuals, excess TNF in agents can be used by themselves or in combination the blood is blocked naturally, but in those who have with other medications such as prednisone, rheumatic conditions, higher levels of TNF in the methotrexate, hydroxychloroquine, leflunomide blood can lead to more inflammation and persistent or sulfasalazine. TNF inhibitors may be given by injection under the the same site is not used multiple times. Infliximab and skin or by infusion into the vein. There are pamphlets golimumab infusions are administered at a doctor’s and videos that can teach you how to give yourself office or an infusion center. These treatments take up an injection under the skin. Physicians, nurses, and to 4 hours. The time that it takes for the medication to pharmacists can also teach you how to give the injection. have an effect may vary by patient.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]